Neuren Pharmaceuticals Ltd has released a press release.
FDA approval for Angelman IND and Phase 2 trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuren Pharmaceuticals Limited on 6ix
In the deck
Story so far
Earlier from Neuren Pharmaceuticals
- 2021 Results - a transformational year for Neuren
- Preliminary Final Report and 2021 Full Year Accounts
- Notification regarding unquoted securities - NEU
- Q4 2021 quarterly activity and cash flow report
- Positive topline results from Phase 3 trial in Rett syndrome
Later from Neuren Pharmaceuticals
- S&P DJI Announces March 2022 Quarterly Rebalance
- Ethics approval for Angelman Phase 2 trial in Australia
- FDA approval for Phelan-McDermid IND and Phase 2 trial
- FDA approval for Pitt Hopkins syndrome IND and Phase 2 trial
- Neuren appoints Chief Medical Officer in United States
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals